960 results on '"Greco, Raffaella"'
Search Results
52. Nanosphere’s Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance
53. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications
54. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
55. P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
56. S260: IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CAR T-CELL THERAPY: INTERNATIONAL SURVEY AND CONSENSUS GUIDELINES ON ITS GRADING, DIAGNOSIS, AND MANAGEMENT ON BEHALF OF EHA AND EBMT
57. PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
58. P1539: INFECTION-RELATED MORTALITY CLINICAL-BIOLOGICAL SCORING SYSTEM (IRM-SCORE) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A VALIDATION STUDY IN GITMO CENTRES
59. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases
60. A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation
61. Activation Tagging Using the En-I Maize Transposon System in Arabidopsis
62. Blast resistance R genes pyramiding in temperate japonica rice
63. Slaying the "Troll of Transplantation"—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023.
64. Function Search in a Large Transcription Factor Gene Family in Arabidopsis: Assessing the Potential of Reverse Genetics to Identify Insertional Mutations in R2R3 MYB Genes
65. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant
66. Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease
67. Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP
68. Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients
69. Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: A pilot experience
70. Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience
71. Editorial: Real-world data and real-world evidence in hematologic malignancies
72. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia
73. Intrabone transplant of a single unwashed umbilical cord blood unit with ATG-free and sirolimus-based GvHD prophylaxis: fast immune-reconstitution and long-term disease control in 30 patients with high-risk diseases
74. Chapter 12 - Hematopoietic stem cell transplantation for neuromyelitis optica spectrum disorder. Can immune tolerance be reestablished?
75. Chapter 19 - The EBMT-ADWP and the CIBMTR
76. Chapter 3 - The hematopoietic niche and the autoreactive memory in autoimmune disorders
77. Chapter 15 - Autologous hematopoietic stem cell transplantation for pediatric autoimmune neurologic disorders
78. Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome
79. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
80. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
81. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study
82. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA
83. Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases
84. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
85. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
86. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells
87. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation
88. Editorial: Real-world data and real-world evidence in hematologic malignancies
89. Pre-engraftment neurological impairment in allogeneic stem cell transplant: A case report of atypical posterior reversible encephalopathy syndrome with pontine involvement
90. Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
91. Continuous and Differential Improvement in Worldwide Access to Hematopoietic Cell Transplantation: Notable Increase of HCT for Non-Malignant Indications and from Non-Identical Related Donors
92. Levofloxacin prophylaxis vs no prophylaxis in neutropenic patients within an endemic country for carbapenem-resistant GNB
93. Patients Reported Outcomes (PROs) Are Still Unsatisfactory Among AML Long-Term Survivors: The Impact of Chronic GvHD in a Prospective Study on 15 Years Transplant Activity
94. Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients
95. Interaction between the GROWTH-REGULATING FACTOR and KNOTTED1-LIKE HOMEOBOX Families of Transcription Factors
96. Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches
97. Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on Cytomegalovirus reactivation risk after allogeneichematopoietic stem cell transplantation
98. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning
99. Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
100. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.